[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rare-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rare-cancer":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,80,106,129,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100278638","ontario-wide-cancer-targeted-nucleic-acid-evaluation-100278638",false,"NCT02906943","Ontario-wide Cancer TArgeted Nucleic Acid Evaluation","OCTANE","Inclusion Criteria:\n\n1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.\n2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.\n3. Patient must be ≥ 18 years old.\n4. Patient's ECOG performance status equal to 0 or 1.\n5. All patients must have a life expectancy of \\> 6 months.\n6. All patients must have adequate organ functions.\n7. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent\u002Fmetastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.","ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.\n\nBiomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.\n\nThe study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.\n\nAnother goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.\n\nThe study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.",[24,25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Colorectal Cancer","Melanoma","Gynecological Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Cancer",[36,37,38,39,40],"Molecular Profiling","Advanced Cancer","Advanced Solid Tumors","Phase I Clinical Trial Candidates","Next Generation Sequencing","RECRUITING","2026-06-03",{"date":44,"type":45},"2026-06-05","ACTUAL",{"date":47,"type":4},"2016-08",{"date":49,"type":20},"2027-08",{"name":51,"class":52},"University Health Network, Toronto","OTHER",7,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":21,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100581809","treatment-guided-by-comprehensive-genome-and-transcriptome-analysis-versus-standard-of-care-in-advanced-rare-cancers-100581809","NCT06855134","Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers","Randomized Comparison of Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Patients With Advanced Rare Cancers (RATIONALE)","RATIONALE","Inclusion Criteria:\n\n* Age ≥ 18years, no upper age limit\n* Patients with locally advanced and\u002For metastatic rare epithelial or mesenchymal cancer (equal numbers of patients) without curative treatment option\n* Progressive disease or expected progression of the disease estimated by clinical parameters, suitable biomarkers, and other (e.g. radiographic) methods \\* At least one measurable lesion that has been accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and is amenable to repeat evaluation in MRI\u002FCT images\n* Patients must have received at least one standard therapy for advanced disease according to current guidelines or consensus recommendations or have no standard therapy available\n* Possibility to perform fresh tumor biopsy according to local SOPs or Availability of fresh frozen tumor samples with sufficient tumor cell content collected within 3 months prior to enrolment\n* ECOG PS ≤ 2.\n* Ability of patient to understand character and consequences of the clinical trial\n* Patient must be willing and able to undergo subsequent treatment (e.g. in a clinical trial) with molecularly guided therapy according to the MTB recommendation\n* Availability of complete information about all medical treatment given before study participation, i.e. remission status before start of treatment, dosage and timing of drugs applied, remission status and date of progression after treatment\n\nExclusion Criteria:\n\n* Dementia or significant cognitive impairment\n* Epilepsy requiring pharmacologic treatment\n* Prior allogeneic bone marrow or solid organ transplantation\n* Hematological malignancies and primary brain tumors.\n* Prior comprehensive molecular profiling by WGS, WES, RNA-Seq, or large targeted panels.\n* Patients with symptomatic or uncontrolled brain metastases and patients with symptomatic or uncontrolled spinal cord compression. Patients with previously treated brain metastases are eligible, provided that the patient has neither experienced a seizure nor had a clinically significant change in neurological status within the three months prior to enrollment. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month, both prior to study enrollment.\n* Malignancy other than study indication within the last 5 years except: curatively treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, low-risk prostate cancer, or other malignancies curatively treated with no evidence of disease for ≥5 years.\n* History of intracranial hemorrhage or spinal cord haemorrhage; no ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted\n* Known uncontrolled or significant cardiovascular disease, including any of the following:\n* History of heart failure NYHA class 3 or 4\n* History of uncontrolled angina pectoris, arrhythmias, or myocardial infarction within 12 months prior to screening.\n* History of liver cirrhosis\n* Neurologic or psychiatric disorder interfering with ability of giving informed consent.\n* Known or suspected active alcohol or drug abuse.\n* Patients with inability to receive oral medications.\n* Failure to provide consent for the registration, storage, and processing of individual disease characteristics and clinical course, as well as for informing the primary care physician about the participant's involvement in the study.",{"count":63,"type":20},946,"48 Months","Rare cancers, defined by an incidence of fewer than 6 cases per 100,000 persons per year, constitute nearly 25% of adult malignancies. They are associated with poor patient outcomes due to incomplete biological understanding and inadequate representation in clinical trials. To address this gap, the DKFZ\u002FNCT\u002FDKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program, developed by NCT and DKFZ, integrates whole-genome\u002Fexome sequencing (WGS\u002FWES), RNA sequencing (RNA-seq), and genome-wide DNA methylation profiling to inform clinical decision-making in patients with advanced rare cancers. This approach has demonstrated significant improvements in overall response rates (ORR) in 24% and disease control rates (DCR) in 55% of cases, with a progression-free survival (PFS) ratio greater than 1.3 in 36% of patients.\n\nThe randomized, multi-basket, phase II, Italian multicenter ROME study conducted among pretreated patients with metastatic cancer, demonstrated that targeted therapy guided by comprehensive genomic profiling and molecular tumor board (MTB) recommendations significantly improved overall response rate and progression-free survival. Additionally, the study revealed a substantial long-term PFS benefit extending to 12 months and beyond. Although the toxicity profiles differed between the targeted therapy and standard-of-care groups, the incidence of adverse events was comparable. These findings, reported at the ESMO Congress 2024, emphasize the pivotal role of MTBs in advancing precision oncology through a tumor agnostic, molecularly guided therapeutic approach.\n\nThe objective of the randomized, multicentric, diagnostic RATIONALE trial is to evaluate the efficacy of molecularly guided treatment versus standard treatment in patients with rare cancers by comparing progression-free survival (PFS) between the two arms: an immediate molecular profile-informed treatment arm (MPI arm) and a standard treatment arm with molecular profile-informed treatment upon progression or intolerable toxicity after standard therapy (MPP arm).\n\nPatients with rare epithelial and mesenchymal neoplasms are evenly randomized in a 1:1 ratio to either the MPl arm or MPP arm. Comprehensive molecular profiling includes WGS and RNA-seq for both arms. A multidisciplinary MTB evaluates these molecular profiles and provides clinically relevant management recommendations, including diagnostic reevaluation, genetic counseling, and molecularly informed treatment options. Recommendations may include matching patients to molecularly stratified clinical trials or - if no suitable clinical trials can be identified - coordinated applications will be provided for off-label use in routine clinical care. The primary efficacy endpoint is progression-free survival (PFS), whereas secondary endpoints are overall survival (OS), overall response rate (ORR), disease control rate (DCR) after three and six months, and patient-reported outcomes (PROs).\n\nBased on data from the MASTER cohort, it is anticipated a median PFS of three months with treatment selected by the physician's discretion. Drawing on findings from the CRAFT trial (ClinicalTrials.gov: NCT04551521), MTB-guided treatment is expected to positively impact the primary endpoint with a hazard ratio (HR) ranging from 0.4 to 0.6. Assuming 30% implementation rate of MTB recommendations, a sample size of 756 eligible patients will be required to demonstrate a significant improvement in PFS with immediate MTB guided treatment, yielding an HR of 0.5 for the MPI arm and overall study HR of 0.7862. The calculation is based on a type 1 error of 5% and a statistical power of 90%. Considering a conservative estimate that that 20% of patients will not be evaluable, the total rounded required sample size is 946 patients.",[33],[68,69],"Molecular tumor board","molecularly informed treatment recommendation","2026-05-07",{"date":72,"type":45},"2026-05-12",{"date":74,"type":45},"2025-09-29",{"date":76,"type":20},"2030-04",{"name":78,"class":52},"German Cancer Research Center",16,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240","NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.\n2. Prior allogeneic stem cell transplant",{"count":88,"type":20},7000,"This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[24,25,27,91,29,30,31,32,33,92],"Gynecologic Cancer","Unknown Primary Tumors",[94,95,96],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","2026-05-06",{"date":99,"type":45},"2026-05-11",{"date":101,"type":45},"2026-03-31",{"date":103,"type":20},"2031-03-31",{"name":51,"class":52},1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":105},"100573475","registry-study-on-rare-cancers-in-korea-100573475","NCT06746766","Registry Study on Rare Cancers in Korea","rarecancer","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Confirmed rare cancer\n* Life expectancy ≥3 months\n\nExclusion Criteria:\n\n-Serious or unstable medical\u002Fpsychiatric conditions","19 Years",{"count":115,"type":20},500,"5 Years","This study aims to determine the participation rate of patients with registered rare cancers in clinical research.",[33],[33],"2026-04-27",{"date":122,"type":45},"2026-04-30",{"date":124,"type":45},"2024-11-18",{"date":126,"type":20},"2027-12-01",{"name":128,"class":52},"Yonsei University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":138,"conditions":139,"keywords":146,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":105},"100342582","genomic-investigation-of-unusual-responders-100342582","NCT03740503","Genomic Investigation of Unusual Responders","GENIUS","Inclusion Criteria:\n\n1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.\n\n   1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months\n   2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)\n2. The patient must have sufficient archival tumor available for sequencing.\n3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:\n\n   a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.\n\n   b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program\n\n   Exclusion Criteria:\n   * None",{"count":137,"type":20},100,"Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and\u002For other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.",[140,24,141,26,29,28,142,143,144,33,145],"Cancer","Non-small Cell Lung Cancer","Upper Aerodigestive Tract Cancer","Pancreatobiliary Gastrointestinal Cancer","Melanoma (Skin)","Carcinoma of Unknown Primary",[140,24,147,26,29,28,142,143,148,33,34],"Non- small Cell Lung Cancer","Melanoma Cancer","2025-01-30",{"date":151,"type":45},"2025-01-31",{"date":153,"type":45},"2013-11-01",{"date":155,"type":20},"2025-11",{"name":51,"class":52},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":105},"100375248","phase-2-a-phase-ii-study-on-adjuvant-vaccination-with-dendritic-cells-loaded-with-autologous-tumor-homogenate-in-resected-stage-iv-rare-cancers-100375248","NCT04166006","A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.","A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).","RaC-Ad","Inclusion Criteria:\n\n1. Patients must have histologically confirmed stage IV Head\\&Neck Squamous Cell Carcinoma (HNSCC), NeuroEndocrine Tumors (NET) or Soft Tissue Sarcoma (STS) surgically treated with radical intent.\n2. The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab and must fulfil all the acceptance criteria prescribed by the Good Manufactory Practice (GMP) procedures.\n3. The patient must be disease-free, as assessed by CT scan or MRI of the chest, abdomen, pelvis performed within 60 days before enrolment. If the resected lesions occurred in other sites, these must be also included in the baseline CT scan and in all the subsequent evaluations.\n4. Patients disease-free candidates for only observation as per clinical practice (no standard treatment is available after surgery)\n5. The patient must have recovered from all the adverse events related to previous surgery.\n6. Age ≥18 years.\n7. Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.\n8. Patient must have acceptable organ function, defined as:\n\n   1. Haemoglobin \\>10 g\u002Fdl\n   2. White blood cells ≥3000\u002Fμl.\n   3. Absolute neutrophil count ≥1500\u002Fμl.\n   4. Platelets≥75000\u002Fμl.\n   5. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C3 times the upper institutional reference level.\n   6. Total bilirubin \\\u003C1.5 times the upper institutional reference level.\n   7. Serum creatinine \\\u003C1.5 times the upper institutional reference level.\n9. Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.\n10. Female patients of childbearing potential and all male patients must accept and be compliant with an highly effective contraceptive method (i.e. with a failure rate of \\\u003C1% per year: double barrier method, one barrier method plus spermicidal, intrauterine device, or oral contraception) from informed consent signature and up to three months after end of study. For this purpose are considered of childbearing potential all female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile. Complete abstinence from sexual intercourses is acceptable if patients' lifestyle guarantees his\u002Fher strict compliance with this prescription in the judgement of the Investigator.\n11. The patient is willing and able to give written informed consent for the study.\n\nExclusion Criteria:\n\n1. Patients with residual disease after surgery. Marginal resection of any lesion in the absence of clinically evident residual disease is acceptable.\n2. Patient who completed surgery more than 90 days before study enrolment.\n3. History of other neoplastic diseases in the previous 5 years, except basal cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with curative surgery.\n4. History of congenital or acquired immunodeficiency, including history of organ transplantation.\n5. Any positivity for the serologic markers of hepatitis B virus (HBV) (including at least anti- Hepatitis B surface antibodies (HBs) and hepatitis B core (HBc) antibodies, hepatitis C virus (HCV), HIV or Treponema pallidum. The serologic tests must have been performed within 30 days before any GMP-regulated activity (i.e. surgical resection and leukapheresis). The sole positivity for antibodies against the HBV surface antigen (i.e.\n\n   with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable.\n6. Female patients who are pregnant or nursing.\n7. Participation in another clinical trial with any investigational agent within 30 days prior to study screening.\n8. Any active inflammatory or autoimmune disease requiring systemic steroids or other immunomodulatory agents as detailed in section 6.4, or potentially requiring such treatments during the study treatment in the judgement of the Investigator.\n9. Any clinical condition that, in the opinion of the Investigator or the Transfusion Medicine specialist, is a contraindication to leukapheresis. In addition, all patients aged 70 or older must be evaluated by a cardiology specialist before the procedure to exclude any clinically relevant cardiac condition and any grade 3-4 cardiac arrhythmia, even if asymptomatic.\n10. Any uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations potentially impacting patient safety and compliance in the opinion of the Investigator.\n11. Refusal of giving written informed consent.",{"count":166,"type":20},51,"INTERVENTIONAL",[169],"PHASE2","Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head\u002FNeck tumors (H\\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).",[172,173,174,33,175],"Head Neck Tumors","Neuroendocrine Tumors","Soft Tissue Sarcoma","Vaccination",[172,173,174,177,178,179,180,181],"rare cancer","vaccination","autologous dendritic cells","adjuvant","Interleukin-2","2024-09-17",{"date":184,"type":45},"2024-09-19",{"date":186,"type":45},"2019-12-12",{"date":188,"type":20},"2031-12",{"name":190,"class":52},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS"]